CliffBio
small molecule

EDARAVONE

EDARAVONE

Loss of exclusivity—loss of exclusivity
CompanyLong Grove →See this company's full patent-cliff portfolio

Drug detail

Brand nameEDARAVONE
Active ingredientEDARAVONE
Strength30MG/100ML (0.3MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2024
Marketing statusDISCN

More from Long Grove

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.